Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sutherlandia frutescens extract is a botanical preparation derived from a South African legume traditionally used in indigenous medicine to treat a variety of conditions, including cancer, HIV/AIDS, and inflammatory diseases. The extract contains several bioactive compounds such as L-canavanine, pinitol, GABA, and sutherlandiosides. Research indicates that the extract may exert antineoplastic effects by inhibiting the Hedgehog (Hh) signaling pathway, a key regulator of cell differentiation and proliferation that is often dysregulated in cancers. Specifically, it has been shown to repress the expression of Hh-responsive genes, including the transcription factor Gli1 and the receptor Ptch1, in prostate cancer models. While widely available as a dietary supplement, its clinical application as a standardized therapeutic agent remains under investigation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sutherlandia frutescens extract.